Interim Management Statement
Reed Elsevier
First Nine Months Trading in Line with Expectations, Full Year
Outlook Reaffirmed
Reed Elsevier, the global professional information company, has today
issued a statement relating to the first nine months trading performance
and outlook for the full year.
-
Underlying revenue growth +4% (+3% excluding the effect of biennial
exhibition cycling).
-
All five business areas contributing to underlying growth.
-
On track to deliver underlying revenue and profit growth in line with
expectations.
Chief Executive Officer, Erik Engstrom, commented:
“In the first nine months of 2012 we have made good progress in
systematically transforming our business, primarily through organic
investment, supplemented by selective portfolio developments. The macro
economic environment and its impact on our customers’ markets remain
uncertain, but by focusing on the fundamentals of our business, we
expect to continue to improve the quality of our earningsâ€.
Nine month trading performance and full year 2012 outlook by business
area:
Elsevier
-
Underlying revenue growth +2%.
-
Growth in databases and tools has remained strong. Double digit growth
in usage and submissions has continued to drive good revenue growth in
scientific and health research. Continued declines in print books and
pharma promotion revenues.
-
In August 2012 the management structure of Elsevier was reorganised,
combining the leadership of Science & Technology and Health Sciences.
The pro forma revenue streams that formerly made up Science &
Technology would have grown +5% underlying in the first nine months,
and Health Sciences would have remained flat.
-
Full year outlook: We expect the trends for the first nine
months to continue, with good growth in electronic revenues and
declines in print books and pharma promotion.
LexisNexis Risk Solutions
-
Underlying revenue growth +6%.
-
Insurance solutions growth +7%, underpinned by good growth in
established and new applications and services. Business Services
growth +6% reflecting demand for risk management tools across
financial institutions and other corporate customers.
-
Continued modest growth in Screening, largely driven by new product
initiatives and new business wins. Good growth in state & local
government revenues. Moderating declines in federal government
revenues.
-
Full year outlook: We expect the good growth in Insurance and
Business Services to continue. Screening continues to be subject to US
hiring, and the outlook for government spending remains mixed.
LexisNexis Legal & Professional
-
Underlying revenue growth +1%.
-
Growth in usage and new sales of online research and litigation tools,
partially offset by declines in print books and listings.
-
Roll out of the new technology platform is on track and new
applications have been well received by customers. Plans for
international releases on the New Lexis platform are proceeding well.
-
Full year outlook: Customer markets remain subdued reflecting
the uncertain economic conditions in many of our markets. We expect
the trends of the first nine months to continue as we execute against
our plans to improve the business.
Reed Exhibitions
-
Underlying revenue growth +15% (+7% excluding biennial cycling); first
half annual exhibition phasing reversed in Q3, eliminating phasing
impact on year to date growth rate.
-
Strong growth in the US. Modest growth in Europe, with good growth in
core franchises moderated by slowing growth in southern Europe.
Outside the US and Europe strong growth continued, with emerging
markets growth well into double digits.
-
New launch activity focused on high growth sectors and geographies,
with 20 new launches in the first nine months.
-
Full year outlook: Full year results will reflect positive
biennial cycling. Excluding cycling, we expect strong growth outside
Europe to continue. Growth rates in Europe will continue to be
impacted by the economic environment in southern Europe.
Reed Business Information
-
Underlying revenue growth +1%.
-
Major Data Services continued to generate good underlying growth, with ICIS,
BankersAccuity and XpertHR all delivering double digit
growth, moderated by continued weakness in US construction data.
-
Leading Brands and Online Marketing Solutions saw some growth, but
revenue from Other Magazines & Services continued to decline.
-
Full year outlook: We expect the trends of the first nine
months to continue, with good growth in Major Data Services partially
offset by declines in Other Magazines & Services.
Portfolio development and share buy backs
-
We intend to continue to transform our business through organic
development, and by disposing of businesses that no longer fit our
strategy. We expect disposals to be mildly dilutive to EPS in the
short term, and we intend to use gross divestment proceeds to buy back
shares, mitigating this impact.
-
Based on transactions either completed or well progressed so far this
year, we are raising the amount that will be deployed on share
buybacks this year to £250m (€310m), of which £158m (€193m) has
already been deployed. In the event that additional disposals are
completed or announced this year, gross disposal proceeds will also be
used to buy back shares.
Balance sheet
-
Reed Elsevier’s financial position remains strong with good cash
generation.
-
Since the interim results we have issued €550m of 8 year term debt at
a coupon of 2.5%, and $560m of 10 year term debt with a coupon of
3.125%. Related to these transactions, we have retired $300m of high
coupon term debt.
- ENDS -
Enquiries
Paul Abrahams (Media)
Tel : +44 20 7166 5724
Colin Tennant (Investors)
Tel: +44 20 7166 5751
Notes to editors
About Reed Elsevier
Reed Elsevier Group plc is a world leading provider of professional
information solutions to the science, medical, legal, risk management,
and business to business sectors. The group employs more than 30,000
people, including 16,000 in North America. Reed Elsevier Group plc is
owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV; the combined market capitalisation of the two parent
companies is approximately £13bn/€16bn. Their shares are traded on the
London, Amsterdam and New York Stock Exchanges using the following
ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.